CMND-100

Sept. 08, 2026: Clearmind Medicine Inc. (NASDAQ: CMND) said Yale University’s IRB approved initiation of patient recruitment for Parts B and C of its Phase I/II trial of CMND-100 in Alcohol Use Disorder (AUD), enabling enrollment at Yale School of Medicine’s Department of Psychiatry. The multicenter study is titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND-100 in Healthy Volunteers and Subjects with AUD.”

Yale joins other active sites including Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The Yale site is led by Anahita Bassir Nia, MD.

The company also reiterated previously announced Part A results from the ongoing FDA-regulated Phase I/II study: all 24 participants across four ascending-dose cohorts completed treatment per protocol; the primary endpoint of safety and tolerability was achieved; CMND-100 showed a consistent safety profile through the dose-escalation phase, including the highest dose in cohort 4; and no serious adverse events were observed. The update indicates the program is advancing into further recruitment for Parts B and C.